持续滴注诺维本联合异环磷酰胺治疗铂类耐药的非小细胞肺癌的临床研究  

Continuous Intravenous Dripping of Navelbine Combined with Ifosfamide in Treatineot of Platinum-Resistant Non-Small Cell Lung Cancer

作　　者：潘战宇[1] 闫祝辰[1] 谢广茹[1] 王毓敏[1] 乔卉[1] 

机构地区：[1]天津医科大学附属肿瘤医院中西医结合科,天津市300060

出　　处：《中国肿瘤临床》2001年第5期361-364,共4页Chinese Journal of Clinical Oncology

摘　　要：目的：临床研究持续性静脉滴注诺维本（ Ｎａｖｅｌｂｉｎｅ，ＮＶＢ）联合异环磷酰胺（Ｉｆｏｓｆａｍｉｄｅ，ＩＦＯ）治疗铂类耐药的非小细胞肺癌（ＮＳＣＬＣ）的疗效与毒副反应。方法：入组非小细胞肺癌２７例，临床予持续性静脉滴注ＮＶＢ联合ＩＦＯ化疗，至少两个疗程，疗效及毒性判定按照ＷＨＯ标准。结果：有效率为１８．５％。在毒副反应方面，表现不同程度的白细胞下降、血小板下降。结论：本项研究提示持续性静脉滴注ＮＶＢ联合ＩＦＯ方案治疗铂类耐药的非小细胞肺癌有较高疗效，并较为安全，患者可接受。Objective: To evaluate the effect of continuous intravenous dripping of navelbine (NVB) combined with ifosfamide (IFO) in treatment of platinum agents resistant non-small cell lung cancer (NSCLC). Methods: Twenty-seven cases of NSCLC were treated with combination chemotherapy consisting of continuous dripping of NVB and IFO for at least two cycles. The therapeutic effects and toxicity were evaluated according to the WHO criteria. Results: The total response rate was 18.5% and the main side-effects were leukopenia in some extent and thrombocytopenia, and in some cases, nausea and vomiting were observed. Conclusion: The results of this study shows that continuous dripping of NVB combined with IFO has a safe and higher therapeutic effect on NSCLC.

关 键 词：联合化疗 诺维本 持续性滴注 临床研究 非小细胞肺癌 异环磷酰胺 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]